- Home
- PCH vs XENE Comparison
PCH vs XENE Comparison
Compare PCH & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCH
- XENE
- Stock Information
- Founded
- PCH 1903
- XENE 1996
- Country
- PCH United States
- XENE Canada
- Employees
- PCH N/A
- XENE N/A
- Industry
- PCH Real Estate Investment Trusts
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- PCH Real Estate
- XENE Health Care
- Exchange
- PCH Nasdaq
- XENE Nasdaq
- Market Cap
- PCH 3.0B
- XENE 2.4B
- IPO Year
- PCH N/A
- XENE 2014
- Fundamental
- Price
- PCH $40.56
- XENE $30.97
- Analyst Decision
- PCH Strong Buy
- XENE Strong Buy
- Analyst Count
- PCH 7
- XENE 11
- Target Price
- PCH $49.86
- XENE $54.82
- AVG Volume (30 Days)
- PCH 566.7K
- XENE 838.3K
- Earning Date
- PCH 07-28-2025
- XENE 08-07-2025
- Dividend Yield
- PCH 4.44%
- XENE N/A
- EPS Growth
- PCH 7.03
- XENE N/A
- EPS
- PCH 0.61
- XENE N/A
- Revenue
- PCH $1,102,209,000.00
- XENE $7,500,000.00
- Revenue This Year
- PCH $2.63
- XENE N/A
- Revenue Next Year
- PCH $4.86
- XENE $253.71
- P/E Ratio
- PCH $66.83
- XENE N/A
- Revenue Growth
- PCH 10.86
- XENE N/A
- 52 Week Low
- PCH $36.82
- XENE $26.74
- 52 Week High
- PCH $48.12
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- PCH 51.41
- XENE 44.77
- Support Level
- PCH $40.63
- XENE $30.84
- Resistance Level
- PCH $42.52
- XENE $32.72
- Average True Range (ATR)
- PCH 0.91
- XENE 1.08
- MACD
- PCH 0.04
- XENE -0.16
- Stochastic Oscillator
- PCH 29.24
- XENE 27.43
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.